BR112022006279A2 - Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 - Google Patents
Heteroaril-bifenil aminas para o tratamento de doenças pd-l1Info
- Publication number
- BR112022006279A2 BR112022006279A2 BR112022006279A BR112022006279A BR112022006279A2 BR 112022006279 A2 BR112022006279 A2 BR 112022006279A2 BR 112022006279 A BR112022006279 A BR 112022006279A BR 112022006279 A BR112022006279 A BR 112022006279A BR 112022006279 A2 BR112022006279 A2 BR 112022006279A2
- Authority
- BR
- Brazil
- Prior art keywords
- heteroaryl
- diseases
- treatment
- compounds
- biphenyl amines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
HETEROARIL-BIFENIL AMINAS PARA O TRATAMENTO DE DOENÇAS PD-L1. A presente invenção refere-se a compostos que são úteis como imunomoduladores. Os compostos têm a Fórmula (I) incluindo estereoisômeros e sais farmaceuticamente aceitáveis dos mesmos, em que R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 e n têm as definições fornecidas no presente documento. Também são fornecidos métodos associados à preparação e ao uso de tais compostos, bem como composições farmacêuticas que compreendem tais compostos. (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915771P | 2019-10-16 | 2019-10-16 | |
| PCT/US2020/055669 WO2021076688A1 (en) | 2019-10-16 | 2020-10-15 | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022006279A2 true BR112022006279A2 (pt) | 2022-06-28 |
Family
ID=75538872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022006279A BR112022006279A2 (pt) | 2019-10-16 | 2020-10-15 | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11866429B2 (pt) |
| EP (1) | EP4045037A4 (pt) |
| JP (1) | JP2022551972A (pt) |
| KR (1) | KR20220083775A (pt) |
| CN (1) | CN114555080A (pt) |
| AR (1) | AR120246A1 (pt) |
| AU (1) | AU2020368392A1 (pt) |
| BR (1) | BR112022006279A2 (pt) |
| CA (1) | CA3152714A1 (pt) |
| CL (1) | CL2022000955A1 (pt) |
| CO (1) | CO2022004698A2 (pt) |
| CR (1) | CR20220216A (pt) |
| EC (1) | ECSP22038509A (pt) |
| IL (1) | IL291735A (pt) |
| MX (1) | MX2022004450A (pt) |
| PE (1) | PE20221764A1 (pt) |
| TW (1) | TW202128695A (pt) |
| WO (1) | WO2021076688A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1 |
| CN114206338A (zh) | 2019-07-10 | 2022-03-18 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-ASSOCIATED DISEASES |
| CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
| CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| ES2589736T3 (es) | 2006-03-31 | 2016-11-16 | Novartis Ag | Derivados de piridina como inhibidores de DGAT |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| CN103958497B (zh) | 2011-11-14 | 2017-09-01 | 亚尼塔公司 | 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物 |
| US8993756B2 (en) | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CA2922655A1 (en) | 2013-09-06 | 2015-03-12 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| JP6521977B2 (ja) | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての１，２，４−オキサジアゾール誘導体 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6767096B2 (ja) | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| TW201710250A (zh) | 2015-05-13 | 2017-03-16 | 賽爾維他股份公司 | 經取代之喹喏啉衍生物 |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109153670B (zh) | 2016-05-23 | 2022-03-15 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109890819B (zh) | 2016-06-20 | 2022-11-22 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
| CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
| EP3483142A1 (en) | 2016-07-05 | 2019-05-15 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| EA201990221A1 (ru) | 2016-07-08 | 2019-06-28 | Бристол-Маерс Сквибб Компани | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TW201823199A (zh) | 2016-09-02 | 2018-07-01 | 美商北極星藥品公司 | 免疫檢查點抑制劑、組成物及其方法 |
| US10882844B2 (en) | 2016-12-20 | 2021-01-05 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| PE20191532A1 (es) * | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| ES2899402T3 (es) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CN106674136B (zh) | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
| WO2018121560A1 (zh) | 2016-12-29 | 2018-07-05 | 深圳微芯生物科技有限责任公司 | 脲类化合物、其制备方法及其应用 |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| JP7150745B2 (ja) | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018196768A1 (zh) | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| EP3658522B1 (en) | 2017-07-28 | 2021-12-22 | ChemoCentryx, Inc. | Immunomodulator compounds |
| US10392405B2 (en) | 2017-08-08 | 2019-08-27 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
| US11787766B2 (en) | 2017-08-18 | 2023-10-17 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CA3075638A1 (en) | 2017-09-25 | 2019-03-28 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| CN109956898B (zh) | 2017-12-22 | 2021-03-26 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| WO2019128918A1 (zh) | 2017-12-29 | 2019-07-04 | 广州再极医药科技有限公司 | 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用 |
| WO2019147662A1 (en) | 2018-01-23 | 2019-08-01 | Bristol-Myers Squibb Company | 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators |
| KR102534185B1 (ko) | 2018-02-05 | 2023-05-18 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | 비아릴 유도체, 이의 합성법과 그 약학적 용법 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1 |
| EP3759093B1 (en) | 2018-03-01 | 2022-11-30 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN111788193B (zh) | 2018-03-13 | 2023-04-04 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
| MX2020010321A (es) | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| WO2019192506A1 (en) | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| MX2020012045A (es) | 2018-05-11 | 2021-03-29 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de ligando 1 de muerte programada (pd-l1). |
| WO2020011209A1 (zh) | 2018-07-11 | 2020-01-16 | 上海和誉生物医药科技有限公司 | 免疫抑制剂及其制备方法和在药学上的应用 |
| WO2020011243A1 (en) | 2018-07-12 | 2020-01-16 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US20210300909A1 (en) | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| WO2020015716A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| CN112638899B (zh) * | 2018-08-01 | 2023-09-05 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
| US20210236476A1 (en) | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| MA55974A (fr) | 2019-05-15 | 2022-03-23 | Chemocentryx Inc | Composés triaryles pour le traitement de maladies pd-l1 |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
| BR112021023750A2 (pt) | 2019-06-20 | 2022-01-11 | Chemocentryx Inc | Compostos para tratamento de doenças pd-l1 |
| CN114206338A (zh) | 2019-07-10 | 2022-03-18 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-ASSOCIATED DISEASES |
| EP4045039A4 (en) | 2019-10-16 | 2023-12-13 | Morphic Therapeutic, Inc. | INHIBITION OF HUMAN INTEGRIN ALPHA4BETA7 |
| IL299206A (en) | 2020-06-23 | 2023-02-01 | Chemocentryx Inc | Methods for treating cancer using heteroaryl-biphenyl amide derivatives |
-
2020
- 2020-10-15 KR KR1020227016266A patent/KR20220083775A/ko unknown
- 2020-10-15 WO PCT/US2020/055669 patent/WO2021076688A1/en unknown
- 2020-10-15 JP JP2022522679A patent/JP2022551972A/ja active Pending
- 2020-10-15 BR BR112022006279A patent/BR112022006279A2/pt unknown
- 2020-10-15 US US17/071,056 patent/US11866429B2/en active Active
- 2020-10-15 EP EP20877362.2A patent/EP4045037A4/en active Pending
- 2020-10-15 MX MX2022004450A patent/MX2022004450A/es unknown
- 2020-10-15 PE PE2022000617A patent/PE20221764A1/es unknown
- 2020-10-15 CN CN202080073055.9A patent/CN114555080A/zh active Pending
- 2020-10-15 AU AU2020368392A patent/AU2020368392A1/en active Pending
- 2020-10-15 CA CA3152714A patent/CA3152714A1/en active Pending
- 2020-10-15 CR CR20220216A patent/CR20220216A/es unknown
- 2020-10-16 AR ARP200102872A patent/AR120246A1/es unknown
- 2020-10-16 TW TW109135945A patent/TW202128695A/zh unknown
-
2022
- 2022-03-27 IL IL291735A patent/IL291735A/en unknown
- 2022-04-13 CO CONC2022/0004698A patent/CO2022004698A2/es unknown
- 2022-04-14 CL CL2022000955A patent/CL2022000955A1/es unknown
- 2022-05-13 EC ECSENADI202238509A patent/ECSP22038509A/es unknown
-
2023
- 2023-11-29 US US18/522,995 patent/US20240132495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022551972A (ja) | 2022-12-14 |
| EP4045037A1 (en) | 2022-08-24 |
| PE20221764A1 (es) | 2022-11-11 |
| TW202128695A (zh) | 2021-08-01 |
| US20210130347A1 (en) | 2021-05-06 |
| KR20220083775A (ko) | 2022-06-20 |
| ECSP22038509A (es) | 2022-06-30 |
| IL291735A (en) | 2022-05-01 |
| CO2022004698A2 (es) | 2022-04-29 |
| AU2020368392A1 (en) | 2022-04-21 |
| CL2022000955A1 (es) | 2023-01-13 |
| WO2021076688A1 (en) | 2021-04-22 |
| CR20220216A (es) | 2023-01-09 |
| EP4045037A4 (en) | 2023-11-15 |
| CN114555080A (zh) | 2022-05-27 |
| CA3152714A1 (en) | 2021-04-22 |
| US11866429B2 (en) | 2024-01-09 |
| AR120246A1 (es) | 2022-02-09 |
| US20240132495A1 (en) | 2024-04-25 |
| MX2022004450A (es) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022659A2 (pt) | Compostos triarílicos para o tratamento de doenças pd-l1 | |
| BR112021023750A2 (pt) | Compostos para tratamento de doenças pd-l1 | |
| BR112022006279A2 (pt) | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 | |
| BR112022006018A2 (pt) | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 | |
| BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
| BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112018009281A8 (pt) | composições para tratar atrofia muscular espinhal | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
| CU20170109A7 (es) | Derivado de quinoleina para tratar y prevenir infecciones virales | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| BR112014010105A2 (pt) | aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112019004248A2 (pt) | inibidores da dopamina-b-hidroxilase | |
| BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
| BR112021020295A2 (pt) | Agentes antiproliferativos para o tratamento de pah | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112017015693A2 (pt) | ciclopropabenzofuranil piridopirazinadionas |